

COVID-SAFER: Deprescribing Guidance for Nirmatrelvir-ritonavir Drug Interactions in Older Adults

Running title: COVID-SAFER

Sydney B. Ross MSc¹, Émilie Bortolussi-Courval NClin.^{2,3}, Ryan Hanula BSc^{2,3}, Todd C. Lee MD MPH FIDSA^{2,3,4}, Marnie Goodwin Wilson* MD MSc FRCPC⁵, Emily G. McDonald* MD MSc FRCPC^{2,3,6}

- 1) Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada
- 2) Centre for Outcomes Research and Evaluation, McGill University Health Centre, Montreal, Quebec, Canada
- 3) Division of Experimental Medicine, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
- 4) Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
- 5) Division of General Internal Medicine and Division of Critical Care Medicine, University of British Columbia, Vancouver, British Columbia, Canada
- 6) Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada

*For the purposes of authorship Dr. Wilson and Dr. McDonald contributed equally

Financial Disclosure: This project did not receive any funding

Corresponding Author:

Emily G. McDonald MD MSc
emily.mcdonald@mcgill.ca
Office 3E.03 5252 De Maisonneuve Boulevard
Montréal, QC, Canada
H4A 3S9

Abstract: 283

Word count: 1839

Tables and Figures: 3

Key words: polypharmacy; Paxlovid; Nirmatrelvir-ritonavir; COVID-19; Deprescribing

Impact Statement:

We certify that this work is novel. This timely clinical investigation explores the unforeseen consequences of polypharmacy and the use of potentially inappropriate medication in older adults during the COVID-19 pandemic. This manuscript addresses the many drug-drug interactions between nirmatrelvir-ritonavir, an antiviral treatment for COVID-19, and potentially inappropriate medications in older adults with polypharmacy from the MedSafer cluster randomized trial. Our work highlights that the pandemic has created an even greater urgency to examine the medication lists of older adults and proactively deprescribe to improve the safety and tolerability of different COVID-19 treatments.

Key Points:

- **Question:** How does polypharmacy affect the eligibility of older adults to receive Nirmatrelvir-ritonavir?
- **Findings:** 68% of older adults in the MedSafer cluster randomized trial had a DDI with nirmatrelvir-ritonavir, and 21% were taking at least 1 potentially inappropriate medication.
- **Meaning:** Due to its potent CYP3A4 inhibition, nirmatrelvir-ritonavir is associated with many drug-drug interactions (DDI).

Abstract

Importance: Older adults, at high-risk of developing complications from COVID-19, could benefit from nirmatrelvir-ritonavir, an oral antiviral treatment for outpatients at high risk of complications from COVID-19; however, due to its potent CYP3A4 inhibition, nirmatrelvir-ritonavir is associated with many drug-drug interactions (DDI).

Objectives: Identify how common DDIs are between nirmatrelvir-ritonavir, common medications, and PIMs in older adults with polypharmacy. Craft anticipatory deprescribing guidance for PIMs that interact with nirmatrelvir-ritonavir to help prioritize deprescribing resources, and increase the proportion of older adults potentially benefitting from treatment.

Design: In this secondary analysis, we retrospectively analyzed all patients in the MedSafer cluster randomized deprescribing trial (N=5698 participants) to investigate the proportion of older adults (age >65) with polypharmacy (≥ 5 usual home medications) who would be ineligible for treatment with nirmatrelvir-ritonavir due to pre-existing DDIs.

Setting: The setting of the primary study was in medical inpatient units at 11 Canadian acute care hospitals.

Participants: Hospitalized persons, age 65 years and older, on 5 or more daily home medications, with an expected survival of 3 months or longer were included in this secondary analysis.

Main outcomes and measures: We identified the prevalence of (PIMs), as defined by the MedSafer software. We then developed deprescribing guidance, so clinicians could proactively

deprescribe in an effort to increase the proportion of older adults eligible for safe treatment with nirmatrelvir-ritonavir in the event of a SARS-CoV-2 infection.

Results: Of 5698 participants, a total of 3869 (68%) were taking a medication with a known nirmatrelvir-ritonavir DDI, and of these 823 (21%) had at least one PIM. Of 823 PIMs, 627 (76%) were medications with a known high risk DDI and 213 (26%) were considered moderate risk DDIs with nirmatrelvir-ritonavir. Many of the PIMs required “advanced deprescribing” and could not simply be stopped, held, or adjusted at the time of nirmatrelvir-ritonavir receipt.

Conclusions and relevance: Older adults are at high risk of developing severe complications from COVID-19. Deprescribing PIMs in advance of a COVID-19 infection could increase the proportion of older adults who can safely receive nirmatrelvir-ritonavir, in addition to the usual benefits observed with medication management.

Introduction

Since the beginning of the pandemic, hundreds of thousands of older Americans have died from complications of COVID-19.^[1 2] Despite the availability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, older adults remain one of the most vulnerable populations in terms of hospitalization and death due to COVID-19.^[3] Most recently, there has been a resurgence in cases brought on by new variants such as Omicron.^[4] Exponential spread, viral mutations, and waning of immunity support the need for both an agile vaccination strategy and an ongoing urgency to develop and test effective therapies.^[4 5] On December 22nd, 2021, the FDA granted an emergency use authorization (EUA) for nirmatrelvir-ritonavir (marketed as Paxlovid), the first oral antiviral for the treatment of COVID-19^[6 7]. Nirmatrelvir-ritonavir contains co-packaged tablets of nirmatrelvir (2x150 mg) and ritonavir (100 mg) and is indicated for the outpatient treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.^[8]

An initial randomized clinical trial of nirmatrelvir-ritonavir demonstrated a reduction in risk of all-cause hospitalization or death by 88% (95% CI [75% - 94%]) compared to placebo in high risk, symptomatic, unvaccinated adults with COVID-19.^[6 7] Comparatively, it is one of the most effective treatments for COVID-19 outpatients, among a number of novel or repurposed medications already studied.^[9 10]

During the first wave of the pandemic, one such repurposed medication (hydroxychloroquine) generated significant interest, but ultimately proved to be ineffective in randomized controlled trials.^[11] However, hydroxychloroquine shed light on an important issue:

many older adults could not safely receive this medication or enroll in clinical trials because of important pre-existing drug-drug interactions (DDIs).^[12] Our team conducted an analysis where we theoretically exposed a cohort of 1001 hospitalized older adults to hydroxychloroquine, and found that ~60% of patients had potential DDIs and 43.2% of these involved so-called potentially inappropriate medications (PIMs).^[12] With such a large proportion of patients identified with DDIs due to PIMs and polypharmacy, we called for the rationalization of medication lists in older adults with a focus on medication optimization and proactive deprescribing.

Millions of treatment courses of nirmatrelvir-ritonavir have now been purchased worldwide. Nirmatrelvir-ritonavir also has a long list of DDIs, limiting its safe use, especially among older adults with polypharmacy.^[10] Even with short term use, the ritonavir component strongly inhibits CYP3A4, an important enzyme for the metabolism of many drugs. It therefore has the potential to alter serum concentrations and therefore lead to toxicity or reduced efficacy of several common medications.^[10-13]

Our aims for the present study were two-fold. The first was to identify how common DDIs are between nirmatrelvir-ritonavir, common medications, and PIMs in older adults with polypharmacy. We hypothesized that many patients would not be able to safely receive this oral antiviral. The second aim was to craft anticipatory deprescribing guidance for PIMs that interact with nirmatrelvir-ritonavir to help prioritize deprescribing resources, and ultimately, to increase the proportion of older adults who could benefit from treatment.

Methods

The first COVID-SAFER study was conducted with hydroxychloroquine, using data from the pilot MedSafer study.^[12] For this COVID-SAFER: Nirmatrelvir-ritonavir study, we analyzed data from the 5698 patient cluster randomized MedSafer trial, which ran from August 2017 to January 2020.^[14] Briefly, inclusion criteria identified patients 65-years and older, taking five or more medications, admitted to one of the 11 study hospitals. Data pertaining to medications and comorbidities were analyzed with the MedSafer deprescribing software. The software applies a ruleset for the identification of PIMs which includes common recommendations from expert groups.^[15-17] MedSafer generates a prioritized, individualized deprescribing report according to the perceived level of medication harm (high, intermediate, or low risk/little added value), and provides the rationale for deprescribing with appropriate tapering protocols where required.^[18] The MedSafer trial compared the provision of individualized deprescribing opportunity reports to usual care for the primary outcome of prevention of post-discharge adverse drug events (ADEs) and, among several secondary outcomes, the augmentation of deprescribing of PIMs at hospital discharge.

For the present study, we utilized the data from the MedSafer trial as a representative cohort of older adults with polypharmacy. Over 85% of the patients in the MedSafer study were community-dwelling and all the participants had risk factors for developing severe complications from COVID-19, by virtue of age and comorbidity.

First, we searched the literature for medications with known DDIs with nirmatrelvir-ritonavir by examining the product monograph,^[8] referring to DDI websites and other publications,^[19] and reviewing the exclusion criteria for the randomized controlled trial which led to the EUA (EPIC-HR; NCT04960202).^[20] Medications with known interactions were

grouped according to the American Hospital Formulary Service (AHFS) classification^[21] (Table 1) and divided into two categories: chronic medications and medications typically prescribed for a short course (e.g., antibiotics). We theoretically “exposed” the MedSafer trial cohort to treatment with nirmatrelvir-ritonavir (twice daily for 5 days), identified DDIs, and linked these with the associated potentially harmful outcome, such as medication toxicity, cardiac arrhythmias, increased risk of bleeding, respiratory depression, or death. We classified the DDIs as either severe (e.g., cardiac arrhythmias and respiratory depression) moderate (e.g., increased therapeutic drug level/risk of toxicity) or other (e.g., reduced effectiveness of the drug and/or reduced effectiveness of nirmatrelvir-ritonavir). We further identified the risk of an ADE requiring closer monitoring during therapy (e.g., anti-coagulation parameters or behavioral symptoms; Supplemental Table 1).

Next, we applied the MedSafer rules to determine the proportion of patients receiving one or more PIMs interacting with nirmatrelvir-ritonavir. When present, we also identified the triggering condition associated with each PIM (e.g., orthostatic hypotension, dementia, delirium, renal failure). Finally, we crafted anticipatory deprescribing guidance to avoid potential DDIs. Recommendations were based on the literature and the expert opinion of the authors.^[15-17 19] Ideally, we considered a scenario wherein PIMs were proactively deprescribed weeks to months in advance of ever requiring treatment with nirmatrelvir-ritonavir. As we are aware that such an approach is not always feasible, we also crafted mitigation strategies that included: do not co-administer, hold medication, adjust dose, and/or monitor clinically, based on a prior publication by the authors (Supplemental Table 1).^[12 19]

Of note, we did not account for DDIs with over the counter or naturopathic medications. The most important one being St. John’s Wort, which cannot be co-administered with

nirmatrelvir-ritonavir, as it may lead to loss of virologic response and the possible development of viral resistance.^[22 23] Furthermore, as MedSafer did not capture most systemic chemotherapies, these were not included, but are potentially relevant.

Results

The MedSafer^[18] trial enrolled 5698 patients 65 years and older who were taking 5 or more medications and survived to hospital discharge. The median age of the cohort was 78 years (IQR 71-86) and 50.2% of participants were female. The most prevalent comorbidities were hypertension (74%), type 2 diabetes (39%), ischemic heart disease (34%), and atrial fibrillation (32%). The median number of daily at-home medications was 10 (IQR 8-14), with a median of 2 PIMs (IQR 1-4) identified per participant.

Of the 5698 patients, 3869 (68%) were prescribed one or more usual home medications that could interact with nirmatrelvir-ritonavir. The most commonly prescribed medications with known DDIs were oral antithrombotic medications (e.g., apixaban, warfarin, clopidogrel; 2131/5698 or 37%), statins (e.g., atorvastatin; 1901/5698 or 33%), and alpha1-adrenoceptor antagonists (e.g., alfuzosin, tamsulosin; 779/5698 or 14%) (Table 2). From those with DDIs with nirmatrelvir-ritonavir, MedSafer identified 823/3869 (21%) patients as receiving 1 or more PIMs: 627/823 (76%) with one or more high risk interacting PIMs and 213/823 (26%) with one or more moderate risk interacting PIM. The most common cause of DDIs identified was CYP3A4 inhibition by nirmatrelvir-ritonavir in 34/49 (69%) of the DDIs.

Some common deprescribing opportunities for PIMs included: 1) statins in older individuals with limited life expectancy, 2) antipsychotics for sleep or agitation, 3) opioids for chronic non-cancer pain and 4) alpha-1 blockers in patients predisposed to orthostatic hypotension (Supplemental Table S2).

Discussion

In a representative trial population of older adults with polypharmacy, we found that 68% of older adults were taking one or more medications with a DDI with nirmatrelvir-ritonavir and 21% were prescribed one or more interacting PIMs. Many of these (two thirds) were high risk interactions and some would require advanced deprescribing to allow for treatment with nirmatrelvir-ritonavir (the most obvious example being amiodarone due to its extremely long half-life). In the absence of an advanced plan to deprescribe, many older adults in the cohort would require an alternative COVID-19 therapy because the interactions could not be mitigated by holding the interacting medication.

These findings build on our previous research, calling for proactive deprescribing of PIMs among older adults.^[12] This would not only reduce the general burden of overmedication commonly observed among 40-50% of older adults,^[24] but would also potentially render more people eligible to receive certain COVID-19 therapies. This motivated our secondary study aim which was to craft deprescribing guidance for PIMs that interact with nirmatrelvir-ritonavir to provide clinicians with a practical tool, to help triage deprescribing resources, and to highlight PIMs that should be addressed as soon as possible during the pandemic.

The most common high risk interacting PIMs were lipid lowering agents being given for primary prevention in patients with a limited life expectancy.^[25] Deprescribing statins in this population has the added benefit of improving quality of life.^[25] Also identified were combination antithrombotics/anticoagulants, alfuzosin and tamsulosin in people predisposed to orthostatic hypotension, atypical antipsychotics prescribed for sleep or agitation, and chronic opioids for non-malignancy associated pain. The added benefit of deprescribing these classes of medications is the potential to reduce medication related side effects and harmful ADEs such as

bleeding,^[26] falls,^[27] and fractures.^[28] Of note, opioids for chronic non-cancer pain need to be deprescribed well in advance in order to administer nirmatrelvir-ritonavir due to the risk of acute opioid withdrawal in the absence of tapering.

Limitations of this study are the theoretical nature of the “drug exposure” to only one treatment for COVID-19; however, with millions of courses of nirmatrelvir-ritonavir purchased worldwide, it is expected to be a common exposure. This analysis could also be replicated for other promising potential outpatient treatments, such as fluvoxamine, which also has several DDIs.^[29] We also focused this paper on PIMs; however, the majority of interacting medications were not PIMs. We have provided medication management guidance for many of these medications elsewhere.^[12] It is also important to recognize that stopping PIMs requires clinical judgment when formulating a deprescribing plan. The strength of this study is the large sample size of representative community dwelling older adults with polypharmacy who are at high risk of severe COVID-19 complications; arguably, one of the populations most likely to benefit from treatment with nirmatrelvir-ritonavir.

Conclusion

In this cohort, many older adults were prescribed chronic PIMs that had high risk DDIs with nirmatrelvir-ritonavir. Some of these would need to be stopped well in advance of treatment. We suggest clinicians look to proactively deprescribe PIMs to allow older adult populations to safely benefit from the receipt of promising emerging treatments against COVID-19.

Acknowledgments

We wish to thank the patients who enrolled in the MedSafer study who agreed to participate in research into polypharmacy.

Author contributions: (study concept and design: EGM, TCL, SBR, acquisition of subjects and/or data: EGM, TCL, analysis and interpretation of data: MGW, preparation of manuscript: all authors, revision of the manuscripts: all authors).

Information on author access to data: authors had access to the anonymized primary data from the original MedSafer study, used strictly for the purposes of the primary study and the present secondary analysis.

Financial Disclosure: This project did not receive any funding.

Conflict of interest: Todd Lee and Emily McDonald have received research funding from the Canadian Frailty Network, the Canadian Institutes for Health Research, and the Centre for Aging and Brain Health Innovation for the development of MedSafer. Drs Lee and McDonald, along with McGill University, own the intellectual property to MedSafer and are executives of MedSafer CORP, a for-profit company. Drs. Lee and McDonald receive research salary support from the Fonds de recherche du Québec - Santé.

Sponsor's role: This study was not funded.

Disclaimers: None to disclose

Information on previous presentation of the information reported in the manuscript: The MedSafer study^[18] contains the primary data from which the present study was derived.

References

1. Our World in Data. COVID-19 data explorer.
2. Centre for Disease Control (CDC). COVID-19 Provisional Counts.
3. Miller EA. *The COVID-19 Pandemic and Older Adults*: Routledge.
4. Tong C, Shi W, Zhang A, Shi Z. Tracking and controlling the spatiotemporal spread of SARS CoV-2 Omicron variant in South Africa. *Travel Medicine and Infectious Disease*;46:102252 doi: 10.1016/j.tmaid.2021.102252[published Online First: Epub Date]].
5. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA* doi: 10.1001/jama.2022.0470[published Online First: Epub Date]].
6. FDA. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19.
7. Burki TK. The role of antiviral treatment in the COVID-19 pandemic. *The Lancet Respiratory Medicine* doi: 10.1016/s2213-2600(22)00011-x[published Online First: Epub Date]].
8. Pfizer C. Product Monograph Including Patient Information - Paxlovid. Government of Canada
9. Lee TC, Morris AM, Grover SA, Murthy S, McDonald EG. Outpatient therapies for COVID-19: How do we choose?
10. McDonald EG, Lee TC. Nirmatrelvir-ritonavir for COVID-19. *CMAJ* doi: 10.1503/cmaj.220081[published Online First: Epub Date]].
11. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19. *JAMA*;324(21):2165 doi: 10.1001/jama.2020.22240[published Online First: Epub Date]].
12. Ross SB, Wilson MG, Papillon-Ferland L, et al. COVID-SAFER : Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. *Journal of the American Geriatrics Society*;68(8):1636-46 doi: 10.1111/jgs.16623[published Online First: Epub Date]].
13. Kenworthy, Bloomer, Clarke, Houston. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. *British Journal of Clinical Pharmacology*;48(5):716-27 doi: 10.1046/j.1365-2125.1999.00073.x[published Online First: Epub Date]].
14. McDonald EG, Wu PE, Rashidi B, et al. The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults. *JAMA Internal Medicine* doi: 10.1001/jamainternmed.2021.7429[published Online First: Epub Date]].
15. Choosing Wisely C. Recommendations.
16. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. *Age and Ageing* 2014;44(2):213-18 doi: 10.1093/ageing/afu145[published Online First: Epub Date]].
17. Halli-Tierny AD, Scarbrough C, Carroll D. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults.

- Journal of the American Geriatrics Society 2019;67(4):674-94 doi: 10.1111/jgs.15767[published Online First: Epub Date]].
18. McDonald EG, Wu PE, Rashidi B, et al. The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial. *JAMA Internal Medicine* 2022 doi: 10.1001/jamainternmed.2021.7429[published Online First: Epub Date]].
 19. University of L. Liverpool COVID-19 Interactions.
 20. Pfizer. EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 - Full Text View.
 21. American Society of Health-System P. AHFS Drug Information.
 22. Roby C. St John's Wort: Effect on CYP3A4 activity. *Clinical Pharmacology & Therapeutics*;67(5):451-57 doi: 10.1067/mcp.2000.106793[published Online First: Epub Date]].
 23. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In Vitro Interaction of the HIV Protease Inhibitor Ritonavir with Herbal Constituents: Changes in P-gp and CYP3A4 Activity. *American Journal of Therapeutics*;11(4):262-77 doi: 10.1097/01.mjt.0000101827.94820.22[published Online First: Epub Date]].
 24. Kim J, Parish AL. Nursing: polypharmacy and medication management in older adults. *Clinics in Integrated Care*;8:100070 doi: 10.1016/j.intcar.2021.100070[published Online First: Epub Date]].
 25. Holmes HM, Todd A. Evidence-Based Deprescribing of Statins in Patients With Advanced Illness. *JAMA Internal Medicine*;175(5):701 doi: 10.1001/jamainternmed.2015.0328[published Online First: Epub Date]].
 26. Hansen ML, Sørensen R, Clausen MT, et al. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. *Archives of Internal Medicine* 2010;170(16):1433-41 doi: 10.1001/archinternmed.2010.271[published Online First: Epub Date]].
 27. Fraser L-A, Liu K, Naylor KL, et al. Falls and Fractures With Atypical Antipsychotic Medication Use: A Population-Based Cohort Study. *JAMA Internal Medicine* 2015;175(3):450-52 doi: 10.1001/jamainternmed.2014.6930[published Online First: Epub Date]].
 28. Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J Gen Intern Med* 2010;25(4):310-5 doi: 10.1007/s11606-009-1218-z[published Online First: Epub Date]].
 29. Lee TC, Vigod S, Bortolussi-Courval É, et al. Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis. medRxiv 2021:2021.12.17.21268008 doi: 10.1101/2021.12.17.21268008[published Online First: Epub Date]].

Tables

Table 1. Common Medications with Potential Drug-Drug Interactions with Nirmatrelvir-ritonavir

Interacting Drug Class	Drug Name	Severity	Potential interaction with Nirmatrelvir-ritonavir
Antiarrhythmics	Quinidine Flecainide Propafenone Amiodarone Dronedarone	Severe	CYP3A4 Inhibition may increase the serum concentrations. Potential for serious and/or life-threatening reactions, such as cardiac arrhythmias.
	Digoxin	Severe	P-gp substrate inhibition may increase the serum concentration of digoxin, increasing toxicity.
	Ranolazine	Severe	Potential for serious and/or life-threatening reactions.
Oral antithrombotic agents	Warfarin	Moderate	CYP3A4 Inhibition may decrease serum concentrations Potential for reduced anticoagulation.
	Dabigatran	Moderate	Mixed P-gp substrate inhibition and induction. Increased risk of bleeding, and possible toxicity.
	Rivaroxaban	Severe	CYP3A4 and P-gp substrate Inhibition may increase the serum concentrations, increasing toxicity and risk of bleeding.
	Apixaban	Moderate	
	Edoxaban	Moderate	P-gp inhibition may increase plasma concentrations.
	Ticagrelor	Severe	CYP3A4 inhibition may increase plasma concentrations.
	Clopidogrel	Severe	CYP3A4 induction, decreased plasma concentration. Increased risk of atherothrombotic events.
Anticonvulsants	Phenobarbital Carbamazepine Phenytoin	Other	CYP3A4 induction, decreased plasma concentration and reduced clinical effects of nirmatrelvir-ritonavir.
Lipid Modifying agents	Lovastatin Simvastatin	Severe	CYP3A4 inhibition may increase serum concentrations. Potential for serious myopathy or rhabdomyolysis.
	Atorvastatin, Rosuvastatin	Moderate	
PDE5i	Sildenafil Vardenafil	Severe	CYP3A4 inhibition may increase serum concentrations. Potential for serious hypotension or syncope.
Alpha1-blocker	Alfuzosin	Severe	CYP3A4 inhibition may increase serum concentrations. Potential for serious reactions, such as hypotension.
	Tamsulosin	Moderate	

Antipsychotics	Clozapine Lurasidone Quetiapine Pimozide	Severe	CYP3A4 inhibition may increase serum concentrations. Potential for serious and/or life-threatening reactions, such as cardiac arrhythmias, hematologic abnormalities, and coma.
NSAIDs	Piroxicam	Severe	Potential for life-threatening cardiac arrhythmias.
GI Motility	Cisapride	Severe	Potential for life-threatening cardiac arrhythmias.
Opioids	Fentanyl	Severe	CYP3A4 inhibition, increased serum concentrations. Serious/life-threatening respiratory depression.
	Methadone	Other	CYP3A4 induction, decreased plasma concentration and reduced clinical effect of methadone.
Immuno-suppressants	Tacrolimus	Severe	CYP3A4 inhibition may increase plasma concentrations. Substantial risk for rapid onset of tacrolimus toxicity.
Ergot Derivatives	Ergotamine Ergonovine	Severe	CYP3A4 inhibition may increase serum concentrations. Potential for serious and/or life-threatening reactions,
Sedative hypnotics	Sedative hypnotics	Severe	CYP3A4 inhibition may increase serum concentrations. Potential for extreme sedation/respiratory depression.
Anti-gout	Colchicine	Severe	CYP3A4 inhibition may increase serum concentrations. Potential for serious and/or life-threatening toxicity.

* Many of these medications are potentially inappropriate only under certain clinical circumstances (please refer to Table 2 for potential triggering conditions); **potential inappropriate medications are indicated in bold.**

PIM= potentially inappropriate medication; CNS= central nervous system; NSAIDs=nonsteroidal anti-inflammatory; PDE5i=phosphodiesterase-5-inhibitors.

Not listed in this table are the following medications with important drug-drug interactions with nirmatrelvir-ritonavir: estrogen containing hormone contraceptives; chemotherapies; antifungals (e.g., voriconazole) and antimycobacterials (e.g., rifampin); long-acting inhaled beta agonists (e.g., salmeterol) as these were not collected in the MedSafer study.

Table 2. Prevalence of Drug-Drug interactions with Hypothetical Nirmatrelvir-ritonavir Exposure

AHFS classification	Generic drug name	Proportion of patients prescribed; N(%)
Cardiac and Vascular Drugs		
20120414	Apixaban	602 (10.6)
20120408	Warfarin	551 (9.7)
201218	Clopidogrel	447 (7.8)
20120414	Rivaroxaban	375 (6.6)
240408	Digoxin	225 (4.0)
24040420	Amiodarone	126 (2.2)
20120412	Dabigatran	111 (1.9)
201218	Ticagrelor	42 (0.7)
24040412	Flecainide	11 (0.2)
24040412	Propafenone	10 (0.2)
24040404	Quinidine	5 (<0.1)
24040420	Dronedarone	3 (<0.1)
20120414	Edoxaban	3 (<0.1)
Cholesterol Medications		
240608	Atorvastatin	1725 (30.3)
240608	Simvastatin	166 (2.9)
240608	Lovastatin	10 (0.2)
Vascular Dilating/Bronchodilating or Vascular Constricting Medications		
12160412	Tamsulosin	744 (13.1)
12120812	Salmeterol	424 (7.4)
12160412	Alfuzosin	35 (0.6)
241212	Sildenafil	23 (0.4)
241212	Vardenafil	5 (<0.1)
Medications acting of the CNS		
28160804	Quetiapine	264 (4.6)

849200	Tacrolimus	89 (1.6)
280808	Fentanyl	56 (1.0)
281292	Carbamazepine	44 (0.7)
281212	Phenytoin	35 (0.6)
282408	Diazepam	28 (0.5)
280808	Methadone	20 (0.4)
282404	Phenobarbital	8 (0.1)
28160804	Clozapine	5 (<0.1)
28160804	Lurasidone	5 (<0.1)
282408	Midazolam (Oral)	5 (<0.1)
282408	Triazolam	2 (<0.1)
Gastrointestinal/miscellaneous		
921600	Colchicine	117 (2.1)
8122830	Rifampin	8 (0.1)
81408	Voriconazole	2 (<0.1)
28080492	Piroxicam	1 (<0.1)

No patients were on the following medications: Ranolazine, Lomitapide, Ergotamine, Dihydroergotamine, Ergonovine, Methylergonovine, Pimozide, Cisapride, Ethinyl estradiol containing hormonal contraception.